NCT03602859 2025-12-31
FIRST
Tesaro, Inc.
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT03574779 2025-07-15
OPAL
Tesaro, Inc.
Phase 2 Completed
NCT06023862 2025-06-15
DOVE
Yonsei University
Phase 2 Recruiting
NCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
NCT05751629 2023-04-21
COHORT-A
Tesaro, Inc.
Phase 2 Completed
NCT04679064 2021-08-27
NItCHE-MITO33
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Unknown
NCT03806049 2021-07-15
Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3 Withdrawn